Resverlogix Corp
Company Profile
Business description
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
Contact
4820 Richard Road South West
Suite 300
CalgaryABT3E 6L1
CANT: +1 403 254-9252
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
18
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,465.00 | 44.50 | 0.53% |
CAC 40 | 7,393.76 | 13.02 | 0.18% |
DAX 40 | 20,024.66 | 115.52 | 0.58% |
Dow JONES (US) | 42,297.04 | 247.18 | -0.58% |
FTSE 100 | 8,260.09 | 87.07 | 1.07% |
HKSE | 19,623.32 | 436.63 | -2.18% |
NASDAQ | 19,198.96 | 111.83 | -0.58% |
Nikkei 225 | 39,894.54 | 386.62 | -0.96% |
NZX 50 Index | 13,110.74 | 159.27 | -1.20% |
S&P 500 | 5,850.25 | 31.38 | -0.53% |
S&P/ASX 200 | 8,201.20 | 42.10 | 0.52% |
SSE Composite Index | 3,262.56 | 89.20 | -2.66% |